echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Xuzhou strives to build innovative drug R & D center and promote the development of pharmaceutical industry

    Xuzhou strives to build innovative drug R & D center and promote the development of pharmaceutical industry

    • Last Update: 2017-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network industry trends] recently, Xuzhou City formulated the implementation plan for promoting the development of biomedical industry Xuzhou will promote the development of pharmaceutical industry in scale, intensification and park, and create a number of industrial clusters with standardized management, friendly environment, outstanding characteristics and high industrial relevance We will improve the "seven in one" open networked pharmaceutical collaborative innovation system for government, industry, University, research and financial research, and encourage local key enterprises to step up the evaluation of generic drug consistency The application of intelligence, in-depth integration of the development of medical and health industry, and constantly improve the research and development level and market share of protein generic drugs and original research drugs in Xuzhou In addition, Xuzhou also encourages leading enterprises to introduce or cultivate supporting enterprises from outside the city, and biomedical industry enterprises to increase the purchase of local supporting products, which shall be supported by 1% of the new purchase amount of industrial enterprises in the previous year Biomedical industry is an important part of the "3 + 3" strategic emerging industry system established by Xuzhou Accelerating the development of biomedical industry is of great significance for Xuzhou to realize the continuous transformation of new and old driving forces, cultivate new driving forces for economic development, and increase the health and well-being of the masses Recently, Xuzhou City has formulated the implementation plan for promoting the development of biomedical industry, aiming at building an important innovative drug R & D base in China, highlighting the combination of introduction and training, imitation and creation, focusing on elements and integrating resources, planning and building a number of industrial parks, attracting a number of leading projects, cultivating and expanding a number of key enterprises, stimulating the innovation vitality of the pharmaceutical industry, and extending Expand the industrial chain, promote the agglomeration and open development of the pharmaceutical industry, build the whole industrial chain of R & D, production, logistics and sales, realize the medium and high-speed development and transformation of the industry, and strive to build an important regional biomedical R & D, incubation, production base and large health industry center The guidance and concentration will promote the large-scale, intensive and park oriented development of the pharmaceutical industry, and create a number of industrial clusters with standardized management, friendly environment, prominent characteristics and high industrial relevance Focusing on the development orientation of biomedical industry, we will focus on the construction of "2 + 4" six regional Chinese parks, classify and build protein and central nervous drug manufacturing bases, medical equipment manufacturing bases, chemical new drug bases, pharmaceutical plant production and manufacturing bases, large health industry bases, and Chinese medicine industry bases, cultivate and expand biomedical industry clusters, and accelerate the promotion of relevant production equipment and original The upstream and downstream industrial chain enterprises such as material supply, logistics, sales and service outsourcing develop simultaneously Collaborative innovation resource sharing improves the "seven in one" open network pharmaceutical collaborative innovation system for government, industry, University, research and Research Fund introduction, builds an integrated industrial public service platform covering "third-party testing, research and development consulting services", focusing on the research and development of anti-virus, anti-tumor, hypoglycemic, chemical drugs, biological drugs and traditional Chinese medicine for the treatment of cardiovascular, cerebrovascular, nervous system and other diseases; Accelerate the research and development of advanced medical biomaterials, tissue engineering scaffolds and drug carrier materials Focusing on key directions and technologies in the field of medicine, accelerate the construction of innovation platforms such as pilot test center, enterprise technology center, engineering laboratory and Engineering Research Center, and support enterprises and colleges in the field of biomedicine to establish R & D institutions at or above the provincial level and share public R & D resources Support the construction of "medical" industrial innovation center, build a number of innovation platforms supported by gene bank and stem cell bank, and focus on breakthroughs in gene diagnosis and treatment, anti-tumor drugs, cell transplantation and other technologies We will give prominence to our advantages, make efforts to improve our expertise, and support key leading enterprises to accelerate the evaluation of generic consistency by means of acquisition, merger, trusteeship, equity participation, holding and alliance, focusing on the advantageous fields of protein new drugs, central nervous new drugs, reproductive health, health drinks, etc We will support specialized and characteristic small and medium-sized pharmaceutical manufacturing enterprises to do fine and professional work, focusing on Modern Chinese medicine, biological health care, dialysis instruments, display and detection of antibody preparations, stem cell clinical, gene application, delayed and controlled release preparation technology research, and continue to expand market share Accelerate the industry of recombinant human insulin raw materials and preparations, expand the scale of central nervous drugs, general anesthesia inducing drugs with cardiovascular stability, anti infective drugs and other drugs, promote the modernization of traditional Chinese medicine, and actively promote the R & D and production of pharmaceutical intermediates and end products; We will accelerate the transformation and upgrading of medical devices, highlight new technological development directions such as fusion imaging, non-invasive testing, dynamic testing and treatment, and vigorously develop medical electronic equipment, health monitoring and rehabilitation equipment and other medical devices Develop intelligent health information service products and strive to build an advanced medical equipment manufacturing system Build network development logistics to encourage the merger and reorganization of small and micro enterprises by pharmaceutical distribution enterprises, and promote the scale, intensive and standardized development of enterprises We will guide Bikang Xinyang pharmaceutical logistics and other large enterprises to implement the through train (green channel) service, and improve the modern logistics service level and radiation capacity of large and medium-sized biomedical production enterprises Accelerate the construction of cold chain transportation system for drugs, support the implementation of informatization and standardization, and promote the wide use and cross regional promotion of industry standardization We will encourage large and medium-sized circulation enterprises, such as Enhua pharmaceutical chain, to gradually extend their services to residential communities, villages and towns, and improve the drug security capacity and service level at the grassroots level, relying on a relatively complete marketing and distribution network We will vigorously support the development of e-commerce marketing scale, drug distribution and value-added services, such as biconbourne e-commerce platform, Wan BANGYUN health platform and Xuzhou pharmaceutical e-commerce platform Encourage medical consortia to unify drug bidding and purchase, and give priority to recommending Xuzhou pharmaceutical distribution and wholesale enterprises to participate in distribution Accelerate the use of Internet of things technology and automatic sorting and sorting equipment, reduce the cost of circulation; establish information sharing and feedback traceability mechanism to ensure the safety of medication We will speed up the distribution of drug import and export ports and drug bonded areas, and build a distribution center for international drug distribution and purchase and a drug logistics port Deep integration of application intelligence We will encourage leading pharmaceutical enterprises such as Wanbang, Enhua and Bikang to build intelligent factories and digital workshops, promote the intellectualization of pharmaceutical production process, accelerate the application of big data, cloud computing, Internet, additive manufacturing and other technologies, actively cultivate the development and expansion of Bikang industrial cloud data center, Bikang big data platform and new models such as app, Enhua mobile Internet, Wanbang cloud health, and build a medical industry Crowdsourcing, Internet plus, and personalized customization, the new production mode of drug products, including consumer demand dynamic perception, crowdsourcing design and personalized customization, is mainly supported by Xuzhou Hao Xin Qing mental health care platform, which integrates medical and medical resources with big data technology to build a large-scale online medical platform, and promotes the deep integration of "Internet +" with new medicine and big health industry We will accelerate the digitalization and intellectualization of medical device products, vigorously carry out the development of technical outsourcing (BPO, CRO) in the pharmaceutical industry, speed up the construction of joint-stock hospitals in the Northern District, build a well-known maternity and child care and intelligent elderly care characteristic medical institution in the zhunchai Economic Zone, and accelerate the construction of four-level medical system including comprehensive and specialized hospitals, internationally renowned clinics and intelligent medical communities Open cooperation, deepen exchanges, vigorously carry out industrial chain investment, improve the level of research and development of psychotropic drugs in Xuzhou, and constantly improve the level and market share of research and development of protein generic drugs and original research drugs in Xuzhou We will encourage multinational companies to build high-level pharmaceutical R & D centers, production centers and purchasing centers in Xuzhou, support leading enterprises such as Wanbang and Enhua to carry out international registration and certification, and increase the share of APIs, pharmaceutical preparations and medical devices in the international mainstream market Support the pharmaceutical enterprises in Xuzhou to carry out overseas M & A, equity investment and venture capital, and establish overseas R & D center, production base, sales network and service system Actively connect with national and provincial international production capacity cooperation platforms, build a communication and cooperation platform for Xuzhou pillar enterprises and international peers or technical institutions, and broaden the information and scientific and technological vision of small and medium-sized enterprises To support the implementation of reward guarantee, where an enterprise newly obtains the first or second class production approval documents of national innovative drugs and biological products and lands in Xuzhou City for production and settlement, it will be given a reward of 1 million yuan to the R & D enterprise; The R & D enterprises who have obtained the production approval documents of improved new drugs, drugs listed abroad but not listed in China or other types of biological products, and three types of medical device certificates and have been put into production and settlement in Xuzhou City will be awarded 500000 yuan Enterprises are encouraged to purchase drug inventions, varieties or first generic drug numbers For drug inventions with purchase price of 10 million yuan or more, varieties with purchase price of 50 million yuan or more, first generic drug number with purchase price of 50 million yuan or more and enterprises entering local industrial production, a one-off subsidy of 5% of purchase price shall be given, no more than 3 million yuan If leading enterprises are encouraged to introduce or cultivate supporting enterprises from outside the city, and biomedical industry enterprises increase the purchase of local supporting products, support shall be given according to 1% of the newly increased purchase amount of industrial enterprises in the previous year For pharmaceutical logistics, supply chain, e-commerce and other enterprises with an investment of more than 5 million yuan in the current year, 5% of the actual investment will be given a subsidy, which is no more than 2 million yuan For the newly opened chain stores of local "" pharmaceutical enterprises, 30% of the rent shall be subsidized within three years from the opening, with the subsidy amount no more than 500000 yuan On the basis of the same quality and price, priority should be given to the inclusion of local medical products in the provincial medical insurance and basic drug supplement catalogue, and the shortlisted varieties for bidding and purchasing in the market, so as to improve the market share of local medical products Original title: Xuzhou to build an important innovative drug R & D base in China, teach you to use app (Pharma) in the whole process, seize the opportunity of drug machine
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.